A new name, an old crisis: Metabolic dysfunction at the core of polyendocrine metabolic ovarian syndrome.

Renaming polyendocrine metabolic ovarian syndrome emphasizes its core metabolic dysfunction, highlighting its link to increased cardiovascular and metabolic disease risk.

• Why it matters: Understanding and funding research on this condition is limited due to its historical misclassification, which hampers effective diagnosis and treatment strategies.
• What they did: The authors discuss how changing the disease's name redefines its understanding, aiming to address the underfunding and fragmentation in basic metabolic research related to PMOS.
• The result: This reclassification may improve awareness, research focus, and ultimately lead to better management of the metabolic aspects of the syndrome.